Title: Targeting POGLUT1 to Promote Biliary Development in Mouse Models of Alagille Syndrome
Dr. Hamed Jafar-Nejad received his M.D. from Tehran University of Medical Sciences and learned molecular biology techniques at a research institute in Iran. After one year at the University of Ottawa, he moved to Baylor College of Medicine in Houston. He received his postdoctoral training in Notch signaling and Drosophila neurogenesis with Dr. Hugo Bellen. In December 2006, he started his research group, first at the University of Texas Health Science Center-Houston and later at Baylor, where they continued their studies on the role of glycosylation and deglycosylation in animal development. In recent years, the Jafar-Nejad laboratory has devoted significant effort to understanding the function of human rare disease genes in animal development. These collaborative studies have led to the identification of Poglut1 as a dominant genetic suppressor of the liver phenotypes in a mouse model for Alagille syndrome, the identification of a new form of muscular dystrophy caused by recessive mutations in POGLUT1, and the discovery of several pathways downstream of the deglycosylation enzyme N-glycanase 1 (NGLY1), mutations in which cause a multi-system developmental disorder. This work will likely provide novel insight into how glycans regulate animal development and might help establish new therapeutic approaches for these diseases.
Title: Leveraging tumor-associated alterations in O-glycosylation for cancer immunotherapy
Dr. Avery Posey is an Assistant Professor at the University of Pennsylvania Perelman School of Medicine. He received Ph.D. from the University of Chicago (2011) and his postdoctoral training at the University of Pennsylvania. He is a classically trained molecular and developmental geneticist and an expert in the development and pre-clinical characterization of chimeric antigen receptors (CARs) and other engineered T cell strategies for cancer immunotherapy. His current research is focused on the redirection of T cells to target cancer-specific epitopes, especially glycan haptens and O-glycopeptide epitopes formed through altered glycosylation in cancer cells, investigation of optimal CAR-T signaling for effective anti-tumor responses and durable persistence in solid tumors, and CRISPR/Cas9-mediated gene-editing strategies for improved engineered T cells (knockout of checkpoint molecules - PD-1, CTLA-4, etc.; HDR knock-in of combination therapies). The major objective of his research is to increase the efficacy of engineered T cells in solid tumors.
Title: Human Gut Bacteria Tailor Extracellular Vesicle Cargo for the Breakdown of Diet- and host-derived glycans
Dr. Feldman obtained his Ph.D. at the University of Buenos Aires, Argentina, under the supervision of Dr. Armando Parodi. After completing his postdoctoral training in Guy Cornelis and Markus Aebi labs in Switzerland, he joined the University of Alberta, in Edmonton, Canada, as an assistant professor. In 2015 he moved to the Department of Microbiology at the Washington University School of Medicine in St Louis, USA. The Feldman lab is interested in microbial glycobiology and bacterial pathogenesis. Dr. Feldman has pioneered the field of bacterial glycoengineering, which is a promising approach for the generation of novel bioconjugate vaccines. He has co-founded two companies (VaxAlta and Omniose) in this area. He is a world leader in studying the human pathogen Acinetobacter baumannii and the biogenesis of bacterial extracellular vesicles. Dr. Feldman is a fellow of the American Academy of Microbiology.
Title: Exploring Glycosylation-dependent Pathways as Modulators of Intestinal Inflammation
Dr. Mariño received her Ph.D. in Chemistry from the University of Buenos Aires. She continued her training as a postdoc at the University of Dundee (Scotland, UK) and later, at the National Institute for Bioprocessing, Research, and Training (Dublin, Ireland), integrating her chemical vision of carbohydrates into the biochemistry of glycans and the structural analysis of glycoconjugates in physiological and pathological contexts. After relocating to Argentina, she established the Functional and Molecular Glycomics Lab (Institute of Biology and Experimental Medicine). As an Independent Researcher at CONICET, she focuses on how inflammatory conditions could alter the glycome in inflammatory bowel diseases and colorectal cancer and whether these changes can promote the establishment of altered lectin-glycan interactions and, in doing so, influence the immune response. Her goal is to capitalize on glycoimmunological mechanisms that could potentially re-wire immune circuits in these pathologies, providing novel opportunities for translational medicine.
Based on her glycoanalytical experience, she also offers consultancies on glycosylation analysis to the Latin American Life Sciences Industry. She received several prizes for her work, including the "Carlos B. Udaondo" award from the National Academy of Medicine (2019). She is the current National Representative for Argentina at the International Glycoconjugate Organization.
Title: Sialic acid metabolism in the gut microbiota
Dr. Juge has 25-year expertise in the molecular studies of carbohydrate-protein recognition in gut biology and microbiology, and food biotechnology. She is a deputy leader of the Gut Microbes and Health Institute Strategic Programme at the Quadram Institute Bioscience (QIB, Norwich, UK) and an elected fellow of the Royal Society of Biology. Her previous research at Marseille University (France) and Carlsberg Research Institute (Copenhagen, Denmark) focused on the structure-function relationships of plant and microbial carbohydrate-active enzymes and their potential biotechnological application. Since joining QIB in 2007, she has led a Research Group focusing on the Glycobiology of Host-Microbe interactions in the gut. Currently, her group focuses mainly on defining how gut bacteria adapt to the intestinal mucosal environment and the role of mucin glycans in the crosstalk between the gut bacteria and the host. Their work uncovered novel sialic acid metabolism pathways in gut bacteria, contributing to their fitness in the mucus niche and communication with the host. They are also interested in how cell-surface glycosylation of gut symbionts influences the host immune response. Her Lab is involved in initiatives promoting Glycosciences in Europe, such as Sweet Crosstalk or Glytunes multidisciplinary European Training Networks or CarboMet academic-industry network.
Chang Gung Memorial Hospital and University, Taiwan
Title: Cancer immunotherapy targeting glycosphingolipids (GSLs)
Alice L. Yu, MD, PhD, is an Academician of Academia Sinica, Taiwan. She is a Distinguished Chair Professor & Deputy Director of the Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital and Professor Emeritus at the University of California in San Diego.
As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target glycolipids worldwide. She has continued to improve the efficacy of anti-GD2 immunotherapy through international collaboration. Her group has demonstrated the adverse impact of Globo H expression on the outcome of patients with hepatoma, cholangiocarcinoma, and gallbladder cancer. She also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and angiogenic factor, providing rationales for the ongoing development of Globo H-targeted immunotherapeutics.
She has received many awards, including the Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium (USA) in 2016, The 55th Academic Award from the Ministry of Education (Taiwan), Year 2000 "Key to Life" Award, Leukemia & Lymphoma Society (USA), etc.
Title: Molecular Signals Controlling the Biosynthesis and Biological Activities of Cell Envelope (Lipo)Polysaccharides in Mycobacterium tuberculosis
Dr. Mary Jackson is currently a Professor of Bacteriology in the Department of Microbiology, Immunology, and Pathology at Colorado State University. She earned a Bioengineering degree and an MSc. Degree from the National School of Agronomy, Rennes, France, in 1994, and a Ph.D. in Biochemistry and Cellular and Molecular Biology from the Pasteur Institute, Paris, France, in 1998.
Her research focuses on the elucidation of critical pathways leading to the biosynthesis and export of (glyco)lipids, fatty acids, and polysaccharides in Mycobacterium tuberculosis and other mycobacterial pathogens of clinical interest to inform novel therapeutic strategies.
Dr. Jackson has published over 185 peer-reviewed scientific articles and serves on numerous grant review panels for the National Institutes of Health and other Federal, private, and non-profit funding agencies globally.
Title: Making weak antigens strong: exploiting bacterial outer membrane vesicles for delivering glycans to the immune system
Professor Matthew P. DeLisa is the William L. Lewis Professor of Engineering in the School of Chemical and Biomolecular Engineering at Cornell University. His research focuses on understanding and controlling the molecular mechanisms underlying protein biogenesis--folding and assembly, membrane translocation, and post-translational modifications--in the complex environment of a living cell. He received a B.S. in Chemical Engineering from the University of Connecticut in 1996; a Ph.D. in Chemical Engineering from the University of Maryland in 2001; and postdoctoral work at the University of Texas-Austin, Department of Chemical Engineering. DeLisa joined the Department of Chemical and Biomolecular Engineering at Cornell University in 2003. He has also served as a Gastprofessur at the Swiss Federal Institute of Technology (ETH Zürich) in the Institut für Mikrobiologie. He has garnered a number of honors and awards, including most recently the Biotechnology Progress Award for Excellence in Biological Engineering Publication, and was named the to the inaugural “Life Sciences Power 50” by City & State New York. He is an elected fellow of the American Institute for Medical and Biological Engineering, the American Academy of Microbiology, and the American Association for the Advancement of Science. In recent years, he has served on the IDA/DARPA Defense Science Study Group and the National Academies Committee on Innovative Technologies to Advance Pharmaceutical Manufacturing.
Dr. Vered Padler-Karavani received her PhD in biochemistry from Tel Aviv University. She then did her postdoctoral training with Prof. Ajit Varki at The University of California, San Diego (UCSD) and subsequently established The Laboratory for Glycoimmunology at Tel Aviv University The George S. Wise Faculty of Life Sciences, Department of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research. Her research combines glycobiology, immunology, bio-nanotechnology, cancer research and xenotransplantation, and involves cutting edge technologies within these disciplines. She received several prestigious grants from the European Commission (Marie Curie, Health Consortium, ERC) to investigate various aspects of immunology of carbohydrates. With TRANSLINK health consortium (6 academic institutes, 5 hospitals and 3 companies from Israel, Italy, France, Spain, UK, Sweden, Canada and USA; https://cordis.europa.eu/project/id/603049), she investigated risk factors of animal-derived heart valve implants, in ~5,000 patients. Her research is currently focused on studying mechanisms of glycan immune recognition and responses in animal models and in humans, in vitro and in vivo. Particularly, the immunological basis of anti-carbohydrate antibodies and their implications on cancer and heart diseases, and on developing novel diagnostics and therapeutics for such diseases.
Title: Pectic Glycoconjugates in Plant Cell Walls: Working Toward Understanding their Structure, Synthesis and Function
Dr. Debra Mohnen is a Distinguished Research Professor at the Complex Carbohydrate Research Center and Department of Biochemistry and Molecular Biology, University of Georgia. She studies pectin synthesis, structure, and function with an emphasis on the role of pectin in wall architecture and plant cell growth. She was awarded the Bruce Stone Award in 2008 for pectin synthesis and elected as a fellow of the American Association for the Advancement of Science in 2013. Her research on synthesizing pectin glycan backbones, homogalacturonan, and rhamnogalacturonan, led to the discovery of the GAUT and RGGAT families of glycosyltransferases and the finding that pectin is a family of glycan domains in both cell wall heteroglycans and glycoconjugates. Since 2007 part of her research has been directed at improving plant biomass yield, sustainability, and composition for producing biofuel and biomaterials. As Focus Area Lead of Plant Biomass Formation and Modification in the BioEnergy Science Center, she directed a team of researchers aimed at overcoming biomass recalcitrance to deconstruction, and since 2017 she has served as Research Domain Lead for Integrative Analysis and Understanding in the Center for Bioenergy Innovation. Her current focus is understanding the roles of pectin in cell expansion and wall structure.
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.
Title: Glycan: A Target for Diagnosis and Treatment of Brain Tumors
Professor Atit Silsirivanit received his Ph.D. in Medical Biochemistry from Khon Kaen University in 2011. During 2014-2016, he was supported by the Japan Society for the Promotion of Science (JSPS) to pursue postdoctoral training at the Department of Tumor Genetics and Biology, Kumamoto University, Japan. His current position is as an Associate Professor of Biochemistry at the Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Thailand. His research focuses on the involvement of glycans and glycosylation in the development and progression of cancers, including cholangiocarcinoma, glioblastoma, meningioma, and melanoma. We are currently working on 1) The role of glycans and glycosylation in cancer, 2) Identification of glycobiomarkers for cancer diagnosis, monitoring, and prognostic prediction, and 3) Application of lectins for detection of glycobiomarkers.
Professor Tadashi Suzuki received his Ph.D. (1997) from Department of Biochemistry and Biophysics at University of Tokyo, Japan. He demonstrated the activity and characterized the enzymatic properties of the cytoplasmic peptide:N-glycanase (PNGase/Ngly1) mammalian cells and proposed that this enzyme may be involved in the quality control of newly synthesized glycoproteins. Dr. Suzuki was a postdoctoral fellow at Department of Biochemistry and Cell Biology, State University of New York at Stony Brook (1997-2000). He was an Assistant Professor at University of Tokyo (2002-2004) and a Visiting Associate Professor at Osaka University Graduate School of Medicine (2004-2007). During this period, he identified two cytoplasmic glycosidases, endo-beta-N-acetylglucosaminidase (ENGase) and alpha-mannosidase (Man2C1), involved in the catabolism of free glycans released by the cytoplasmic PNGase. He was a Team Leader at Glycometabolome Team, Systems Glycobiology Research Group, RIKEN. He currently serves as a Chief Scientist at Glycometabolic Biochemistry Laboratory, RIKEN Cluster for Pioneering Research.
His current research interests are (1) clarification of the novel catabolic pathway for glycans on glycoproteins; (2) characterization of biological functions of cytoplasmic peptide:N-glycanase (Ngly1) for the non-lysosomal catabolic pathway of N-glycans; (3) development of new analytical methods for glycans; and (4) development of therapeutics for NGLY1-deficiency.